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INTRODUCTION
Acute rhabdomyolysis is a clinical and laboratory syndrome 
resulting from the breakdown of skeletal muscle, with the re-
lease of intracellular contents into the circulatory system, which 
can cause potentially lethal complications. There are a number 
of possible factors that may lead to acute rhabdomyolysis, and 
many patients present with multiple causes. Here we present a 
patient who developed acute rhabdomyolysis after consump-
tion of meloxicam for jaw pain and experienced generalized 
myalgias in the context of an acute febrile illness with general-
ized urticaria.
CASE REPORT
A 74-year-old, previously healthy male presented to the emer-
gency department with an acute febrile illness, rash, generalized 
myalgias, and jaw pain for 3 days. Examination showed general-
ized urticarial rash with no evidence of lymphadenopathy, mu-
cosal lesions, proximal muscle weakness, or arthropathy. 
The patient had taken meloxicam for the jaw pain for 3 days 
prior to presentation. Three days later, he developed proximal 
muscle weakness of the lower limbs. Laboratory tests revealed 
mild impairment of renal function, eosinophilia, and lympho-
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penia (Table). Muscle enzymes were markedly elevated, and 
serum myoglobin was detected. Viral serology revealed a posi-
tive response for IgM antibody against Ross River virus (RRV), 
suggestive of an acute infection, with negative IgM for hepatitis 
viruses A, B, and C, Epstein-Barr Virus, and Cytomegalovirus. 
Autoimmune serologies were also negative, including antinu-
clear antibody, extractable nuclear antigens, and antineutro-
phil cytoplasmic antibody (Table). Needle muscle biopsy of the 
left vastus lateralis performed at the time of proximal muscle 
weakness showed acute muscle necrosis with features of mito-
chondrial damage. Skin biopsy revealed features consistent 
with urticaria along with mild eosinophilic and neutrophilic in-
filtration without any evidence of vasculitis. Chest X-ray, elec-
trocardiogram, and renal ultrasound were normal. The patient 
was treated with intensive fluid resuscitation, and normaliza-
tion of his muscle enzymes and renal function occurred over 
the course of 1 week. Oral aspirin challenge (1-day protocol with 
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Acute rhabdomyolysis is a clinical and laboratory syndrome resulting from the breakdown of skeletal muscle, with the release of intracellular con-
tents into the circulatory system, which can cause potentially lethal complications. Here, we present the case of a patient who developed acute rhab-
domyolysis after consumption of meloxicam for jaw pain and experienced generalized myalgias in the context of an acute febrile illness with general-
ized urticaria. Further investigation indicated elevated muscle enzymes and acute renal failure. Serological analysis revealed that the patient was 
positive for Ross River virus (RRV) IgM. Genetic studies to detect CYP2C9 polymorphisms were negative. Meloxicam was discontinued. He respond-
ed to conservative measures within 2 weeks. Oral aspirin challenge was negative, suggesting a drug-specific effect of meloxicam rather than a class 
effect. Our case indicates a causative role for meloxicam and/or acute RRV in rhabdomyolysis. 
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incremental doses of ≤600 mg aspirin and a cumulative dose 
of 985 mg) was undertaken to seek a safe alternative, non-ste-
roidal anti-inflammatory drug (NSAID). This was well tolerat-
ed, and no changes in clinical or laboratory parameters, includ-
ing renal function or muscle enzymes, were detected after the 
procedure. Genetic tests to detect CYP2C9 polymorphisms were 
negative. 
The chronology of events suggested a diagnosis of meloxicam-
induced rhabdomyolysis in the context of acute RRV infection. 
Accordingly, the patient was advised to avoid meloxicam in the 
future. 
DISCUSSION
Necrosis of muscle (rhabdomyolysis) is accompanied by the 
release of muscle contents, including myoglobin, creatine phos-
phokinase (CK), potassium, aldolase, lactate dehydrogenase, 
and glutamic-oxaloacetic transaminase, into the serum. Serum 
CK is the most sensitive enzyme marker of muscle injury.
1 
There are a number of possible factors that may lead to acute 
rhabdomyolysis, and many patients present with multiple 
causes. The most common causes are exertion, crush injury, 
seizures, alcohol, viral infections, muscle enzyme deficiencies, 
electrolyte abnormalities, endocrinopathies, drug abuse, and 
statins.
2 Rhabdomyolysis is commonly associated with myo-
globulinuria, which can lead to acute renal failure. Weakness, 
myalgias, and tea-colored urine are the cardinal clinical mani-
festations of rhabdomyolysis.
Drugs are frequently implicated in rhabdomyolysis and may 
directly or indirectly impair muscle metabolism by altering the 
balance between energy production and expenditure.
3 Sarco-
lemmal injury and increased permeability through the activa-
tion of phospholipase A, leading to the efflux of intracellular 
contents and the influx of sodium and calcium, are also pro-
posed mechanisms of drug-induced muscle damage.
4-6 The 
most common causative drugs include antipsychotics and an-
tidepressants, sedative hypnotics, statins, drugs of addiction, 
and antihistamines.
7
There are case reports of rhabdomyolysis induced by NSAIDs
8,9; 
however, rhabdomyolysis due to meloxicam has not been pre-
viously reported. Certain CYP2C9 polymorphisms change the 
metabolism of this class of drug, and thus have been shown to 
increase the risk for rhabdomyolysis. This phenomenon has 
most extensively been reported with celecoxib, a selective cy-
clooxygenase-2 inhibitor.
10,11 In our case, meloxicam was the 
putative cause of our patient’s complications, based on the 
chronological sequence of events (i.e., development of symp-
toms within 3 days of consumption) and the absence of other 
myotoxic drugs. The initial presentation of rash and eosinophil-
ia is suggestive of an allergic reaction to meloxicam. The most 
definitive test for allergy, re-challenge with meloxicam, was 
deemed inappropriate due to the severity of the initial reaction. 
Aspirin challenge confirmed that the reaction was a drug-spe-
cific effect, rather than a class effect of pharmacological inhibi-
tion of arachidonic acid metabolism.
Viral infections may also precipitate rhadomyolysis. Clinical 
presentation can vary in severity from mild myalgias to overt 
muscle injury and acute renal failure in severe cases. Viruses 
implicated in such a reaction include influenza virus A/B, para-
influenza virus, coxsackie virus, Epstein-Barr virus, herpes sim-
plex virus, adenovirus, and cytomegalovirus.
12 Viruses may 
damage muscles directly through the invasion of muscle fibers 
or indirectly through the activation of the immune response.
13-15 
Mosquito-borne alphaviruses, such as RRV, have been reported 
to target bone, joint, and skeletal muscle tissue in a mouse 
model.
16,17 Moreover, histological analyses have demonstrated 
that RRV infection results in severe inflammation of these tis-
sues by infiltrating macrophages, NK cells, and CD4
+ and CD8
+ 
T lymphocytes.
Our patient had taken meloxicam in the context of an acute 
infection with RRV, and the subsequent rapid development of 
rhabdomyolysis suggested a causative role for meloxicam and/
or RRV infection. As we did not perform a meloxicam chal-
lenge, it is unclear whether meloxicam was the primary cause 
or it exacerbated RRV-induced muscle injury. 
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